Clinical trials
Phase 3 Giant Cell Arteritis trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
19 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2002 | 1 |
| 2006 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 4 |
| 2022 | 1 |
| 2024 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 9 |
| Active, not recruiting | 3 |
| Terminated | 3 |
| Recruiting | 2 |
| Not yet recruiting | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Assistance Publique - Hôpitaux de Paris | 2 |
| Centre Hospitalier Universitaire Dijon | 2 |
| Hoffmann-La Roche | 2 |
| Novartis Pharmaceuticals | 2 |
| University Hospital, Caen | 2 |
| AbbVie | 1 |
| Bristol-Myers Squibb | 1 |
| Centre Hospitalier Universitaire de Nice | 1 |
| GlaxoSmithKline | 1 |
| Insel Gruppe AG, University Hospital Bern | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Giant Cell Arteritis | 19 |
| Vasculitis | 3 |
| Arteritis | 2 |
| Polymyalgia Rheumatica | 2 |
| Vascular Diseases | 2 |
| Arthritis, Rheumatoid | 1 |
| Autoimmune Diseases | 1 |
| Blindness | 1 |
| Cerebrovascular Disorders | 1 |
| Granulomatosis with Polyangiitis | 1 |
Trials
Showing 76 to 19 of 19. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.